Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681851 | 0.86 | OPRD1 (0.73) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4685133 | 0.86 | OPRD1 (0.68) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7083219 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6772092 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7086156 | 0.85 | OPRD1 (0.69) | OPRD1OPRM1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6778511 | 0.85 | OPRD1 (0.71) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6769093 | 0.85 | OPRD1 (0.71) | OPRD1OPRM1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6773724 | 0.85 | OPRD1 (0.68) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4680591 | 0.83 | OPRD1 (0.68) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7083492 | 0.83 | OPRD1 (0.68) | OPRD1OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1225465-C | Novel compounds | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | CN | claimed |
| US-6784181-B2 | LIGANDS FOR THE DELTA RECEPTOR | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | claimed |
| EP-1242402-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | EP | claimed |
| CN-1434816-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | claimed |
| US-20030119845-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | claimed |
| EP-1242402-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001045637-A2 | NOVEL 4(PIPERAZINYL (8-QUINOLINYL)METYL)BENZAMIDES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-6784181-B2 | LIGANDS FOR THE DELTA RECEPTOR | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | disclosed |
| EP-1242402-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| US-20030119845-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119845-A1 | Novel compounds | OPRK1, OPRM1, OPRL1 | OPRD1 4/4885OPRM1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.